Sawyer & Company Inc Sells 1,025 Shares of Merck & Co., Inc. (NYSE:MRK)

Sawyer & Company Inc decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,704 shares of the company’s stock after selling 1,025 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.4% of Sawyer & Company Inc’s investment portfolio, making the stock its 20th biggest holding. Sawyer & Company Inc’s holdings in Merck & Co., Inc. were worth $2,071,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRK. JJJ Advisors Inc. bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. PRW Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $41,000. Aspire Private Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $55,000. Thor Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $69,000. Finally, Contravisory Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 19.7% during the 2nd quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock worth $72,000 after purchasing an additional 141 shares during the last quarter. 75.15% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. stock traded up $0.25 during mid-day trading on Wednesday, reaching $83.52. The company’s stock had a trading volume of 8,261,812 shares, compared to its average volume of 9,287,325. Merck & Co., Inc. has a 12-month low of $64.87 and a 12-month high of $87.07. The firm has a market cap of $209.65 billion, a P/E ratio of 19.24, a P/E/G ratio of 1.73 and a beta of 0.57. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 0.82. The stock has a fifty day moving average of $83.15.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $10.94 billion. During the same period in the previous year, the business earned $1.06 EPS. Merck & Co., Inc.’s revenue was up 12.4% compared to the same quarter last year. Equities analysts expect that Merck & Co., Inc. will post 4.74 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be paid a $0.55 dividend. The ex-dividend date is Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.63%. Merck & Co., Inc.’s dividend payout ratio is 50.69%.

In related news, EVP Frank Clyburn sold 25,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $77.73, for a total value of $1,943,250.00. Following the completion of the transaction, the executive vice president now directly owns 92,604 shares in the company, valued at approximately $7,198,108.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard R. Deluca sold 35,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $80.00, for a total transaction of $2,800,000.00. Following the completion of the transaction, the executive vice president now owns 106,064 shares of the company’s stock, valued at $8,485,120. The disclosure for this sale can be found here. Insiders sold a total of 276,718 shares of company stock valued at $23,257,469 over the last quarter. 0.27% of the stock is owned by company insiders.

Several equities research analysts have recently issued reports on MRK shares. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, June 21st. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research note on Friday, June 14th. ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Goldman Sachs Group started coverage on shares of Merck & Co., Inc. in a research note on Tuesday, May 28th. They set a “neutral” rating and a $85.00 price target for the company. Finally, Credit Suisse Group started coverage on shares of Merck & Co., Inc. in a research note on Thursday, July 11th. They set a “buy” rating and a $95.00 price target for the company. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Merck & Co., Inc. presently has an average rating of “Buy” and an average target price of $90.36.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: What is an Initial Public Offering (IPO)?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.